YY1 Is Pivotal in the Control of the Pathogenesis and Drug Resistance of Cancer: A Critical Therapeutic Target describes the current state-of-the-art of the transcription factor YY1 that is overexpressed in the majority of cancers and a central factor that regulates all of the major features and characteristics of human cancers. This book emphasizes the biochemical, molecular and genetic underlying mechanisms by which YY1 regulates its pro-cancerous activities. In addition, it also describes the role of YY1 in the regulation of tumor cell resistance to conventional chemo and immunotherapies and the important role of inhibiting YY1 in cancer.
This book is a valuable source for cancer researchers, oncologists and several members of medical and biomedical field who are interested in understanding further the role of YY1 in cancer.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. General introduction of YY12. Expression of YY1 in various human cancers: Prognostic significance3. Regulation of YY1 transcription and post-transcription4. YY1 and proliferation5. Role of microRNAs targeting YY16. YY1 repression of various genes in various cancers7. YY1 regulation of EMT and metastasis8. YY1 regulation of the cancer stem cell phenotype 9. YY1 regulation of autophagy10. YY1 regulation of resistance to chemotherapy11. YY1 regulation of resistance to immunotherapy12. YY1 phosphorylation13. YY1 epigenetic regulation14. YY1 regulation of the Warburg Effect15. YY1 inhibitors16. YY1 versus YY217. Future perspectives and conclusions
Authors
Benjamin Bonavida Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USA.Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).
